Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Inclusion Criteria: * Subject must have a documented diagnosis of a form of primary humoral immunodeficiency involving a defect in antibody formation and requiring gammaglobulin replacement, as defined according to the IUIS Scientific Committee 2009 and by diagnostic criteria according to Conley et al. The diagnosis must be reviewed by the Medical Director prior to enrollment. * Subject is 2 years or older at the time of screening. * Written informed consent is obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures and study product administration. * Subject has been receiving a consistent dose of immunoglobulin G (IgG) with a non-Baxter product (Gammunex administered IV, Hizentra, or Privigen), administered in compliance with the respective product information, for a period of at least 3 months prior to screening. The average minimum pre-study dose over that interval was equivalent to 300 mg/kg BW/4 weeks and a maximum dose equivalent to 600 mg/kg BW/4 weeks at a dosing frequency as follows: * For IV treatment prior to the study: at mean intervals of 3 or 4 weeks (+/- 3 days) or * For SC treatment prior to the study: at mean intervals of approximately 1 or 2 weeks (+/- 2 days). * Subject has a serum trough level of IgG \> 5 g/L at screening. * Subject has not had a serious bacterial infection within the 3 months prior to screening. * If female of childbearing potential, subject presents with a negative …